Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
Agios announces new clinical data across company’s rare hematology portfolio that will be featured in oral and poster presentations during ASH 2026.
Covered in this story
Call it yourself
No calls on $ASH yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ashland →Dalsna Finance is currently tracking 5 stories mentioning Ashland, the earliest published 4 Nov 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.